Powering Innovation in ILA & ILD Research with Global, AI‑Ready Data
Unlocking Answers for Precision ILD Care
What specific ILD does my patient have? How will they respond to treatment? Will their disease progress? Which therapy offers the best outcome?
These are the critical questions facing healthcare professionals every day in the fight against ILDs. Machine learning offers a transformative solution — by harnessing universal, accessible algorithms to analyze digital patient data, it drives earlier diagnosis, sharper prognoses, and more effective disease management.
The challenge? No single center can gather enough patient data alone to fuel this progress. The OSIC Cloud changes the game. With its vast, diverse, real-world database, OSIC empowers the development of powerful algorithms that uncover answers and save lives. Its open science model ensures that every discovery is shared globally, accelerating personalized treatments and novel drug development for all patients.
Building the OSIC repository has been a collaboration in its truest sense, with people from different disciplines, organizations, and countries all coming together on behalf of patients everywhere. As the OSIC database grows and we continuously learn from it, a real and substantial improvement in our ability to diagnose early, to predict outcomes, and to measure responses to therapy will be the result.
The OSIC Cloud:
Designed to Shape the Future of ILD Care
Developed by a global alliance of radiologists, pulmonologists, machine learning experts, and imaging specialists, the OSIC Cloud is a groundbreaking, data-rich platform.
OSIC’s Collaborative Ecosystem Empowers Discoveries
Each member owns their own discoveries while benefiting from shared resources. Members gain access to rich datasets, platform usage for private and closed-loop trials, and a comprehensive knowledge hub with educational and clinical research resources. It fuels innovation and precision, accelerating breakthroughs in diagnosis and personalized treatment for ILD patients worldwide.
AI-Ready, Highly Secure, and Curated for Breakthroughs
This repository contains diverse, multi-ethnic, and multi-center anonymized scans, clinical data, and longitudinal patient follow-ups, fully compliant with GDPR and HIPAA standards. The OSIC Cloud is vetted by leading global privacy firms, holds U.S. Central IRB (Advarra) and multiple institutional IRB approvals, and adheres to all relevant privacy laws, regulations, consents and restrictions.
Quality Control for Reliable Discovery
Every dataset in the OSIC Cloud undergoes stringent quality control to ensure accuracy and reliability. This solid foundation enables innovation to flourish, unlocking new discoveries, refining digital biomarkers, and transforming patient outcomes at an unprecedented pace.
As a clinical radiologist and researcher focused on interstitial lung diseases (ILD), I’ve seen firsthand how difficult it is to make meaningful progress without access to diverse, well-curated imaging data. OSIC has fundamentally changed the landscape. The OSIC Cloud offers a scale and breadth of imaging and clinical information that simply hasn’t existed in ILD research before.
About The OSIC Cloud Platform
The OSIC Cloud, powered by VIDA, is a secure platform for managing de-identified, curated real-world and clinical trial data — designed to fuel collaborative lung disease research.
Features
Data Security & Privacy Compliance
- GDPR- and HIPAA-compliant architecture
- Robust data backup and security
- Automated cloud-based pseudonymization and anonymization
- Role-based access controls tailored to user types
- Built-in open and restricted access functionality
High-Quality, AI-Ready Data Infrastructure
- Highly curated datasets
- Rigorous QC through automated and manual reviews
- Automated data normalization
Adaptability & Scalability
- Configurable for diverse research workflows
- Disease-agnostic, multi-omic platform
- Support for 13+ languages
Powerful Collaboration & Research Tools
- Smart data upload and customizable contribution tools
- Integrated case viewers
- Annotation tools for collaborative research
- Advanced search and filtering for imaging and clinical data
Expertise Driving Clinical Trial Excellence
- Clinical trial workflows and features optimized for imaging
- Worklist and collection management
- Site training and certification
- 24/5 trial site support for imaging-related questions
- Dedicated Clinical Engagement Team for global site QC and procedures
- Online access to reference materials, including protocols and radiology manuals
Clinical & Educational Impact
- Embedded e-learning platform
Advanced Imaging Tools
The Subpleural Lung in 3D
Transforming Data into Interactive Insights with OSIC Cloud
MULTI-OMIC DATA
Training AI to Detect ILA
OSIC is enabling researchers to train deep learning models to do just that.
- Early ILA detection using LDCT and HDCT
- Stratification of “at-risk” populations
- Potential for earlier treatment and better outcomes
AI + OSIC = New frontiers in preventive pulmonology
Can AI learn a risk score?*
Unlocking Early Detection with AI ILA Risk Scoring
Enabling precision-driven, personalized management; minimizing missed and delayed diagnoses; enhancing outcomes through timely intervention.
Data is the essence of scientific progress, and the OSIC repository already contains preliminary data rich enough to better understand the causes of disease, leading to better treatment and patient outcomes.
The OSIC Cloud ILD Database: Data Overview
The OSIC Cloud
Lung Cancer Screening / ILA / ILD Database
In a recent study of 1,384 individuals who received a lung cancer screening via CT scan, researchers identified “4% ILA in a lung cancer screening cohort; 37% had radiologic progression of ILA at 1 year and 40% were diagnosed with ILD within 5 years. Fibrotic ILA, defined by the presence of traction bronchiectasis, was a strong predictor of mortality, reduced progression-free survival, and diagnosis of ILD.”
The lung cancer cohort in our database will allow for future research to help identify biomarkers that can predict ILA/ILD disease progression.
The presence of ILA on a lung cancer screening is a significant finding that can increase the risk of developing ILD and may be associated with a higher risk of mortality. Early detection and appropriate management of ILA may crucial in preventing the progression to ILD and improving long-term outcomes.
See Innovation in Action:
Real Stories from OSIC Members
Discover how OSIC members and partners are harnessing the power of data to drive breakthroughs. OSIC Videos features compelling presentations that showcase transformative research and real-world impact.
Discover Innovative Research Utilizing the Global AI‑Ready OSIC Dataset
Explore groundbreaking studies using OSIC. Researchers worldwide are leveraging this rich resource to advance understanding and treatment of ILDs. With more than 100 peer-reviewed publications and numerous conference presentations citing OSIC data, the data plays a pivotal role in driving innovation in fibrosing and rare lung diseases.
Accessing The OSIC Cloud
If you are an OSIC Member Institution,
please register to receive access to the OSIC Cloud.
Visit our membership page to learn more.